Iovance Biotherapeutics’ $150 Million Common Stock Public Offering

Pietro Martinoia
Tagged:

DLA Piper advised Iovance, and Latham & Watkins advised the underwriters.Iovance Biotherapeutics, Inc. (Nasdaq: IOVA) announced the pricing of an underwritten public offering of 20,000,000 shares of…

This content is for Standard 1 Year members only.
Login Join Now
Avatar

Author: Pietro Martinoia

…

This content is for Standard 1 Year members only.
Login Join Now